(19)
(11) EP 2 978 845 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.06.2020 Bulletin 2020/25

(45) Mention of the grant of the patent:
29.04.2020 Bulletin 2020/18

(21) Application number: 14713467.0

(22) Date of filing: 27.03.2014
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
A61K 31/713(2006.01)
 C07H 21/02(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/EP2014/056221
(87) International publication number:
WO 2014/154835 (02.10.2014 Gazette 2014/40)

(54)

MODIFIED TGF-BETA OLIGONUCLEOTIDES

MODIFIZIERTE TGF-BETA-OLIGONUKLEOTIDE

OLIGONUCLÉOTIDES DE TGF-BETA MODIFIÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 27.03.2013 EP 13161474
20.06.2013 EP 13173078
30.12.2013 EP 13199826

(43) Date of publication of application:
03.02.2016 Bulletin 2016/05

(73) Proprietor: ISARNA Therapeutics GmbH
80798 München (DE)

(72) Inventors:
  • JASCHINSKI, Frank
    82178 Puchheim (DE)
  • JANICOT, Michel
    1180 Brussels (BE)
  • UHLMANN, Eugen
    61479 Glashütten (DE)

(74) Representative: V.O. 
P.O. Box 87930
2508 DH Den Haag
2508 DH Den Haag (NL)


(56) References cited: : 
EP-A2- 1 008 649
WO-A1-2011/154542
 EP-A2- 2 399 611
WO-A2-2005/084712
   
  • STANTON ROBERT ET AL: "Chemical Modification Study of Antisense Gapmers", NUCLEIC ACID THERAPEUTICS, vol. 22, no. 5, October 2012 (2012-10), pages 344-359, XP055075730,
  • MIHO TAKAGI-SATO ET AL: "Design of ENA gapmers as fine-tuning antisense oligonucleotides with sequence-specific inhibitory activity on mouse PADI4 mRNA expression", NUCLEIC ACIDS SYMPOSIUM SERIES, no. 50, 2006, pages 319-320, XP003021650, ISSN: 0261-3166
  • GORDON, K. & BLOBE, G.: "Role of transforming growth factor-beta superfamily signaling pathways in human disease.", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, vol. 1782, no. 4, 11 February 2008 (2008-02-11), pages 197-228, XP022540518, ISSN: 0925-4439 cited in the application
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).